STOCK TITAN

Immunitybio Inc - IBRX STOCK NEWS

Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.

Overview of ImmunityBio Inc

ImmunityBio Inc (IBRX) is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of next-generation immunotherapies and cell therapies. The company uniquely harnesses the power of both the innate immune system (including natural killer cells and macrophages) and the adaptive immune system (T cells and memory T cells) to create biologic products aimed at treating cancers and combating infectious diseases. With a diversified product platform that includes antibody-cytokine fusion proteins, DNA/RNA/recombinant protein vaccines, and cell-based therapeutic approaches, ImmunityBio provides innovative solutions tailored to activation of multiple immunological pathways.

Integrated and Diversified Therapeutic Platforms

At the core of ImmunityBio's operations is a robust and integrated platform that covers several facets of immuno-oncology and infectious disease therapy. The company’s approach is built around three key modalities:

  • Natural Killer (NK) and T Cell Activation: Utilizing agents like n-803, the company aims to boost the natural cytotoxic functions of NK cells and T cells to target tumor cells directly.
  • Tumoricidal Macrophage Activation: By engaging macrophages, ImmunityBio seeks to leverage the body’s inherent ability to engulf and destroy malignant cells, enhancing the immune system's comprehensive response.
  • Memory T Cell Support: The development of therapies such as Anktiva, an IL-15 superagonist antibody-cytokine fusion protein, is designed to sustain a long-term immune memory that ensures durable protection against disease recurrence.

Operational Structure and Market Strategy

ImmunityBio divides its operations geographically, primarily across the United States and Europe, which allows it to maintain diversified revenue streams and regulatory alignments. The company concentrates on therapeutic areas where unmet medical needs are significant, including bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM). Its dual focus on immuno-oncology and infectious diseases positions it within a competitive landscape that values rapid innovation combined with clinical precision.

Advancements in Clinical Data Management

One of the distinctive aspects of ImmunityBio’s approach is its adoption of innovative technologies to streamline clinical trial operations. In collaboration with a transformational cloud software provider, the company has initiated a partnership to automate the data fulfillment process for clinical trials. By leveraging advanced integration between electronic medical record (EMR) systems and electronic data capture (EDC) platforms, ImmunityBio is set to reduce manual data entry errors and accelerate the speed at which data becomes available for patient safety and trial integrity assessments. This enhanced efficiency not only optimizes trial operations but also reinforces the company’s commitment to data integrity and quality.

Core Strengths and Industry Positioning

ImmunityBio’s approach combines a deep understanding of biological mechanisms with advanced clinical research, placing it at the intersection of biotechnology innovation and practical healthcare applications. The company is recognized for:

  • Scientific Rigor: Its development techniques and molecular platforms are built upon reproducible and scientifically validated methodologies.
  • Platform Diversification: With multiple therapeutic candidates in various stages of clinical development, the company mitigates risks while addressing a range of cancer types and infectious diseases.
  • Operational Integration: The internal expertise spanning clinical research, data management, and regulatory strategy enhances its ability to perform in a competitive market.

Clinical and Product Development Insights

The detailed portfolio at ImmunityBio reflects a commitment to evolving current standards of care. Its product candidates are designed to offer advantages over traditional treatments such as high-dose chemotherapy. Through the use of immune system augmentation, the company's therapies are engineered to be more targeted, accessible, and safe. This philosophical approach underscores the company’s strategic direction, where precision immunotherapies could complement or even replace conventional treatment modalities in select disease areas.

Research, Collaboration, and Data Integration

In today’s data-driven medical research environment, ImmunityBio has embraced collaborations that enhance both the speed and quality of clinical research. The recent initiative to incorporate automated data capture from EMR systems exemplifies the company’s drive to streamline processes while maintaining high standards of data accuracy. This integration is pivotal for ensuring that clinical trials are not only efficient but also yield robust and reliable data. Such efforts are especially critical in fields where translational research and rapid clinical feedback can accelerate the path from research to therapeutic application.

Industry-Specific Innovations

ImmunityBio’s innovative strategies are characterized by their reliance on cutting-edge research and development techniques. Key industry-specific terms such as "cytokine fusion proteins," "cellular immunotherapy," and "vaccine development" illustrate the technical language that underscores its operations. These concepts are crucial in conveying the company’s method of inducing a multifaceted immune response that ultimately results in the destruction of targeted disease cells. Furthermore, its comprehensive research into the synergy between various immune modulators has allowed it to pioneer treatments that are not only effective but also exhibit favorable safety profiles.

Competitive Landscape and Market Relevance

Within the highly competitive realms of immuno-oncology and infectious disease therapeutics, ImmunityBio maintains a distinct market position by integrating advanced data management solutions with its robust research initiatives. While the market includes several entities working on similar immunotherapeutic approaches, ImmunityBio differentiates itself through its versatile platform that covers a broad spectrum of immune activation strategies. This diversity not only provides resilience against market fluctuations but also exemplifies a strategic commitment to comprehensive scientific investigation and clinical validation.

Conclusion

In summary, ImmunityBio Inc represents a complex, multi-faceted approach to modern biotechnology. By focusing on the activation of both innate and adaptive immunity and by integrating advanced digital technologies into its clinical processes, the company offers an integrated model of therapeutic development. Its commitment to rigorous scientific methods, strategic collaborations, and operational excellence makes it a noteworthy subject for those researching innovative approaches in immuno-oncology and infectious diseases. Through detailed analysis and structured clinical development, ImmunityBio continues to contribute significant insights into the future of personalized immunotherapies.

Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) announced that its FDA-approved bladder cancer treatment ANKTIVA® has received a permanent J-code (J9028), effective January 1, 2025. The code will streamline billing and reimbursement processes for the drug, which is approved for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

The company highlighted that ANKTIVA, launched in May 2024, has demonstrated a 71% complete response rate in ongoing QUILT 3.032 study as of November 2024, with response duration up to 54 months. The treatment has secured coverage for over 200 million medical lives through various insurance programs, including VA, DoD, and Medicare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has announced the pricing of its public offering of 33,333,334 shares of common stock at $3.00 per share, expecting to raise approximately $100.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to an additional 5,000,000 shares.

The offering is expected to close around December 12, 2024. The proceeds will be used to advance the commercialization of ANKTIVA® for BCG-unresponsive NMIBC treatment, fund trials in BCG-naïve NMIBC and NSCLC, support research and development, working capital needs, and general corporate purposes. Jefferies and Piper Sandler are serving as joint book-running managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.11%
Tags
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has announced plans for an underwritten public offering of its common stock. The company will grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. Proceeds will fund ANKTIVA® commercialization for BCG-unresponsive non-muscle invasive bladder cancer treatment, trials in BCG-naïve NMIBC and non-small cell lung cancer, R&D activities, working capital needs, and general corporate purposes. Jefferies and Piper Sandler are acting as joint book-running managers, while BTIG and H.C. Wainwright & Co. serve as co-lead managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.11%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) and nCartes have entered a collaboration agreement to automate and streamline clinical trial data fulfillment processes. The partnership aims to replace manual data entry into Electronic Data Capture (EDC) systems with direct digital information transfer from electronic medical record (EMR) systems. This automation initiative is designed to make the process faster, more cost-effective, and reduce potential errors in data entry. The collaboration seeks to improve data quality and reduce the time required for source data verification, potentially accelerating the timeline for bringing therapies to market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has announced new data from its QUILT 3.032 study, where 100 patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC CIS) were treated with ANKTIVA in combination with BCG. The treatment achieved a 71% complete response rate, with durable responses extending up to 54 months. The company plans to submit this updated data to the European Medicines Agency (EMA) in Q4 2024 as part of a Marketing Authorization Application. The results align with previous findings published in the New England Journal of Medicine and demonstrate ANKTIVA's potential in treating patients with treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
none
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) reported Q3 2024 financial results, highlighting $6.0 million in net product revenue from ANKTIVA®, significantly up from $1.0 million in the previous quarter. The company secured coverage for over 200 million medical lives and received a J-code effective January 2025. ANKTIVA's shelf life was extended to three years with 125,000 doses available. The company submitted MAA applications in the UK and plans EU submission in Q4 2024. Financial results showed cash position of $130.4 million, with a net loss of $85.7 million compared to $95.6 million in Q3 2023. R&D expenses increased to $50.4 million, while SG&A expenses rose to $35.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.17%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has initiated dosing in its Phase 1 clinical trial of CAR-NK cell therapy for treating relapsed B-cell Non-Hodgkin Lymphoma. The QUILT 106 trial, testing CD19-targeted high-affinity natural killer cells, represents the first NK cell-based therapy study in Africa. The trial will enroll up to 10 participants across three South African cities. Initially testing the therapy as a single agent, the study will later combine it with rituximab after safety confirmation. Full enrollment is expected in Q1 2025, with topline data anticipated in H2 2025. This trial mirrors the company's U.S.-based QUILT 3.092 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.68%
Tags
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX), an immunotherapy innovator, has announced its participation in the Jefferies London Healthcare Conference. The event is scheduled for November 19-21, 2024 at the Waldorf Hilton London. Company executives will engage in a fireside chat on Tuesday, November 19, 2024, at 2:30 PM GT.

Investors and interested parties can access a replay of the recorded presentation through the Events and Presentations section of ImmunityBio's website at https://ir.immunitybio.com/. The replay will be available for 90 days following the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) presented positive long-term overall survival data for non-small cell lung cancer (NSCLC) patients at the World Conference on Lung Cancer. The Phase 2 QUILT 3.055 trial showed extended survival of 14 months to five years for advanced NSCLC patients treated with ANKTIVA in combination with checkpoint inhibitors like KEYTRUDA or OPDIVO. Key findings include:

- 57% overall survival at 12 months
- 34% overall survival at 18 months
- Survival independent of PDL1 tumor status and line of therapy
- Efficacy in patients who progressed on previous checkpoint inhibitor treatments

Based on these results, ImmunityBio plans to launch global Phase 3 randomized control ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1st and 2nd line NSCLC (ResQ301 and ResQ302) versus standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has made significant progress in market access for ANKTIVA®, its FDA-approved treatment for non-muscle invasive bladder cancer with carcinoma in situ (CIS). Within three months of approval, ANKTIVA® is now covered by over a dozen insurance plans, representing more than 100 million lives. The company is expanding its bladder cancer program globally, initiating the filing process with the European Medicines Agency (EMA) for EU approval and launching a BCG naïve trial (QUILT-2.005) in India.

ImmunityBio has also held an FDA meeting regarding ANKTIVA's potential in Non-Small Cell Lung Cancer (NSCLC) following positive overall survival results in a completed trial. The company is preparing additional study information for a potential NSCLC pivotal trial. These developments mark significant steps in expanding ANKTIVA's reach and potential applications in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags

FAQ

What is the current stock price of Immunitybio (IBRX)?

The current stock price of Immunitybio (IBRX) is $3.14 as of March 28, 2025.

What is the market cap of Immunitybio (IBRX)?

The market cap of Immunitybio (IBRX) is approximately 2.6B.

What is the primary focus of ImmunityBio Inc?

ImmunityBio Inc focuses on developing next-generation immunotherapies and cellular therapies that activate both the innate and adaptive immune responses to treat cancers and infectious diseases.

How does ImmunityBio generate value through its therapeutic platforms?

The company employs a diversified strategy using antibody-cytokine fusion proteins, vaccine candidates, and cell therapies to address various disease mechanisms while optimizing clinical trial operations through innovative data management.

What role does the activation of natural killer and T cells play in its treatments?

Activation of natural killer cells and T cells is central to its approach, as these immune cells help target and destroy malignant cells, while also creating a lasting immune memory to prevent disease recurrence.

How is ImmunityBio improving its clinical trials process?

By partnering with a cloud software platform provider, ImmunityBio is automating the data capture process, integrating EMR systems with EDC platforms to reduce errors and improve data quality in clinical trials.

What therapeutic areas does ImmunityBio primarily target?

The company targets several key areas including various cancers such as bladder, lung, colorectal cancers, and conditions like glioblastoma, along with infectious diseases through its innovative vaccine development.

How does ImmunityBio differentiate itself in the competitive biotech industry?

ImmunityBio distinguishes itself by combining a multi-modal immunotherapeutic platform with advanced digital data integration, ensuring efficient clinical trials and a multifaceted approach to activating the immune system.

What is the significance of the company’s EMR-to-EDC integration?

This integration automates clinical trial data collection, reducing the likelihood of errors and speeding up the availability of high-quality data, which is essential for informed clinical decision-making and regulatory compliance.
Immunitybio Inc

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

2.55B
315.20M
62.9%
9.88%
7.14%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO